DESTINY-Breast07: Conclusions (Results from Part 2/Module 7 [T-DXd in patients with active BMs] as of December 22, 2023 DCO)
Conclusions1
- T‑DXd demonstrates robust overall activity assessed by RECIST v1.1 per investigator; confirmed ORR was 80.0%, median DOR was 18.1 months, and median PFS was 19.5 months
- T-DXd exhibits strong IC efficacy assessed by RANO‑BM per BICR; the confirmed IC ORR was 60.0%, median IC DOR was 14.2 months, and median IC PFS was 15.4 months
- Safety and tolerability are consistent with the known profile of T‑DXd; no new safety signals have been observed and one Grade 5 adjudicated interstitial lung disease event has been reported
Data from larger cohorts of patients with brain metastases will provide further insights
(eg, DESTINY-Breast12 [NCT04739761])
Abbreviations
BICR = blinded independent central review
;BM = brain metastases
;DOR = duration of response
;IC = intracranial
;ORR = overall response rate
;PFS = progression free survival
;RANO-BM = Response Assessment Criteria for Neuro-Oncology Brain Metastases
;RECIST v1.1 = Response Evaluation Criteria in Solid Tumors version 1.1
;T-DXd = trastuzumab deruxtecan
References
1. Anders CP, Loi S, Hamilton E, et al. Safety, tolerability, and antitumor activity of T-DXd in patients with HER2-positive mBC and active brain metastases in DESTINY-Breast07. Poster 185P. Presented at European Society for Medical Oncology-Breast Cancer (ESMO-BC) Annual Meeting; May 15-17, 2024; Berlin, Germany.
Please note that this content may contain some data and/or patient populations which are considered off-label in your country. Providing this information does not constitute any recommendation for use. AstraZeneca is providing this material as an information service and professional courtesy.
To help us improve our content for health care professionals, please take this short survey.
Document ID: 325e86bc-2a1f-401a-b8d6-fa304896a85b
Last updated: 14-February-2023
©2023 AstraZeneca. All rights reserved.